Skip to main content
padlock icon - secure page this page is secure

Open Access TB Vaccine Development

Download Article:
 Download
(PDF 260.2 kb)
 
Tuberculosis (TB) remains one of the major causes of death and disease worldwide. With one quarter of the global population infected with Mycobacterium tuberculosis (M.tb) and over one million annual deaths from the disease, there is an urgent need to develop an effective vaccine. Leading the charge on TB vaccine development is Professor Helen McShane at Oxford University's Nuffield Department of Medicine, UK. Since 2001, Professor McShane has directed the TB vaccine research group with a goal of developing and evaluating new TB vaccine candidates. In doing so Professor McShane has conducted a series of clinical trials in the UK, and high burden TB countries including The Gambia, South Africa, Senegal and Uganda.

To address the inadequate global control of TB, and HIV-associated TB, Professor McShane and her team have developed several new vaccines, the first of which is called Modified Vaccinia Ankara virus expressing antigen 85A (MVA85A). MVA85A was developed as a BCG boost to improve BCG-induced protection against M.tb. Any new vaccine regimen needs to undergo extensive testing. Once found to be effective, a new regimen will be licensed and made available to the public.

Questions regarding the disease transmission cycle, the host protective immune response and the development of vaccines safe in HIV-infected individuals still need to be addressed, before we will have an effective vaccine.

Since 2013, McShane's lab has been pursuing three separate ways to improve the MVA85A vaccine. The first way is to combine the vaccine with another virus that expresses the same antigen, to induce a stronger immune response in the host. The second way is to continue to test the effect of delivering MVA85A by aerosol, as opposed to intradermal injection. Finally, the third way to improve MVA85A is to identify additional novel protective antigens, or molecules that are able to protect the host against infectious and non-infectious diseases, to add in to the Ag85A already in these vaccines.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: AEROSOL DELIVERY; BCG-INDUCTED PROTECTION; CLINICAL TRIALS; IMMUNE RESPONSE; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; NOVEL PROTECTIVE ANTIGENS; TB; TUBERCULOSIS; VACCINATION; VACCINE; VACCINOLOGY; WELLCOME TRUST

Document Type: Research Article

Publication date: March 1, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more